Introduction
============

Population-based colorectal cancer (CRC) screening has been shown to reduce incidence of colon cancer and related mortality [@JR1143-1] [@JR1143-2] . Among patients at average risk, the most favored cancer prevention test is colonoscopy every 10 years, beginning at age 50 (45 for African-Americans) [@JR1143-3] . Screening per 1000 patients using colonoscopy, a gain of 270 life-years and a decrease in 24 deaths from CRC has been estimated [@OR1143-4] .

However, despite being the reference standard, colonoscopy is far from a perfect test. Studies using compute tomography colonography have estimated the sensitivity of colonoscopy for detecting advanced adenomas to be 88 % [@JR1143-5] . Tandem colonoscopy studies have shown that up to one-quarter of polyps are missed during colonoscopy [@JR1143-6] . Adenoma detection rate (ADR) has been shown to be associated with interval colon cancer and related mortality [@JR1143-7] [@JR1143-8] . ADR ≥ 30 % for men and ≥ 20 % for women has been recommended as a quality indicator for colonoscopy [@JR1143-9] . Wide variations in ADRs for endoscopists have been reported [@JR1143-10] [@JR1143-11] . Therefore, various methods have been employed in attempts to improve ADR, including brief educational interventions [@JR1143-12] , use of distal attachments such as caps [@JR1143-13] , third-eye retroscopes, newer-generation wide-angle colonoscopes, cuffs and EndoRings.

Cap-assisted colonoscopy (CC) has been extensively studied as a modality to improve ADR. The cap is a straightforward attachment on the distal end of the endoscope that extends outward beyond the tip of tje colonoscope to varying lengths. The cap helps in deflecting and flattening the mucosal folds, and by keeping the mucosa away from the lens prevents a red-out. These maneuvers expose the proximal aspects of colonic folds and thereby help in detecting polyps in these otherwise blind mucosal areas. Use of cap has been shown to decrease cecal intubation time, increase cecal intubation rate and improve polyp detection rate. However, data on ADR are rather conflicting. The aim of this meta-analysis was to compare the performance of CC with standard colonoscopy (SC) for ADR among high-quality randomized controlled trials (RCT).

Patients and methods
====================

Search strategy
---------------

An electronic search was performed in MEDLINE, EMBASE, Google scholar, Cochrane database and Web of science. The search for studies of relevance was performed using the following key words and corresponding Medical Subject Heading/Entree terms when possible: "CAP assisted colonoscopy," "colonoscopy with distal attachment," "adenoma detection rate," "adenoma per person," "cecal intubation rate," "cecal intubation time" with varying combinations with and/or. We retrieved 2558 abstracts ( [Fig. 1](#FI1143-1){ref-type="fig"} ). Abstracts published in major international conferences, including Digestive Disease Week, United European Gastroenterology Week and Asia Pacific Digestive Week over the past 10 years were manually searched. References from major trials and review articles were manually searched.

![ Study flow diagram depicting search strategy, screening and studies of cap-assisted colonoscopy identified for inclusion in the meta-analysis of adenoma detection rate.](10-1055-a-0650-4258-i1143ei1){#FI1143-1}

From the 2400 records, 2358 records were removed (1473 studies, 927 abstracts) because they were not relevant to the comparison between CC and SC. Of the remaining 42 records, 23 were excluded for the following reasons: duplicity, case report, review article, editorial, abstract only. Of the 19 full-text articles that were accepted, only 7 met the criteria of prospective RCTs, Jadad score  ≥3 (see [Table 1](#TB1143-1){ref-type="table"} ), reported ADR, and these studies were used for ADR and APP (adenomas detected per person) [@JR1143-14] [@JR1143-15] [@JR1143-16] [@JR1143-17] [@JR1143-18] [@JR1143-19] [@JR1143-20] . Of the 42 records, 17 studies were included that compared cecal intubation rate between CC and SC [@JR1143-14] [@JR1143-15] [@JR1143-16] [@JR1143-17] [@JR1143-18] [@JR1143-19] [@JR1143-20] [@JR1143-21] [@JR1143-22] [@JR1143-23] [@JR1143-24] [@JR1143-25] [@JR1143-26] [@JR1143-27] [@JR1143-28] [@JR1143-29] [@JR1143-30] . Thirteen studies were included that compared cecal intubation time between CC and SC [@JR1143-14] [@JR1143-15] [@JR1143-16] [@JR1143-17] [@JR1143-19] [@JR1143-21] [@JR1143-22] [@JR1143-23] [@JR1143-25] [@JR1143-26] [@JR1143-30] [@JR1143-31] [@JR1143-32] . For analysis of cecal intubation and cecal intubation time, even studies with Jadad score \< 3 were included. ADR alone was the primary aim of the study. We removed the constraints for cecal intubation time or rate as we wanted to be less stringent and more inclusive for these endpoints. While ADR is a cornerstone quality indicator for colonoscopy, the other two are not.

###### Studies and their respective Jadad scores.

  Study                                  Final score
  ---------------------- --------------- -------------------------
  Tada 1997              Paper           0
  Matsushita 1998        Paper           1
  Kondo 2007             Paper           3 (No ADR/APP reported)
  Horiuchi 2008          Paper           3
  Shida 2008             Paper           0
  Takano 2008            Abstract        0
  Lee 2009               Paper           1
  Choi 2009              Paper           0
  Harada 2009            Paper           1
  Sato 2009              Prelim Report   3 (No ADR/APP reported)
  Takeuchi 2010          Paper           3
  Tee 2010               Paper           3 (No ADR/APP reported)
  Dai 2010               Paper           0
  Hewett 2010            Paper           3
  Park 2012              Paper           3
  Rastogi 2012           Paper           3
  De Wijkerslooth 2012   Paper           4
  Frieling 2013          Paper           3 (No ADR/APP reported)
  Pohl 2015              Paper           3

Data extraction
---------------

Two investigators (VN and MD) independently reviewed the studies and imported the data into a standardized form. In case of lack of consensus, the senior investigator (AR) reviewed the study independently and then made a final decision regarding the data point.

Data extracted were patient demographics, year of publication, study location, number of subjects, size of adenomas, number of adenomas detected, cecal intubation rate, cecal intubation time and study quality. Individual study and patient characteristics are shown in [Table 2](#TB1143-2){ref-type="table"} .

###### Study characteristics.

  Author                                Country         Sample   CC     SC     Age         Male (%)
  ------------------------------------- --------------- -------- ------ ------ ----------- ----------
  Tada et al. [@JR1143-32]              Japan            140       70     70   60          73
  Matsushita et al. [@JR1143-26]        Japan             24       12     12   59          63
  Kondo et al. [@JR1143-24]             Japan            456      221    235   61          60
  Horiuchi et al. [@JR1143-16]          Japan            835      424    411   64          65
  Shida et al. [@JR1143-28]             Japan            178       82     96   64          51
  Takano et al. [@JR1143-29]            Japan           2502     1287   1215   NA          NA
  Harada et al. [@JR1143-23]            Japan            592      289    303   63          66
  Lee et al. [@JR1143-25]               Hong Kong       1000      499    501   53          46
  Sato et al. [@JR1143-27]              Japan            221      110    111   NA          NA
  Dai et al. [@JR1143-31]               China            250      121    129   51          54
  Hewett et al. [@JR1143-15]            United States    100       52     48   62          57
  Takeuchi et al. [@JR1143-20]          Japan            274      141    133   64          70
  Tee et al. [@JR1143-30]               Australia        400      200    200   54          48
  De Wijkerslooth et al. [@JR1143-14]   Netherlands     1339      656    683   60          51
  Choi et al. [@JR1143-21]              Korea            228      114    114   NA          NA
  Rastogi et al. [@JR1143-19]           United States    420      210    210   61          95
  Park et al. [@JR1143-17]              Korea            600      300    300   62          52
  Frieling et al. [@JR1143-22]          Germany          504      252    252   60 ± 15.5   182
  Pohl et al. [@JR1143-18]              United States   1113      562    551   62          64

Statistical analysis
--------------------

Meta-analyses were performed using Mantel-Haenszel method combining the results from different trials comparing CC and SC. Meta-Analysis was performed according to the PRISMA statement. A complete checklist is provided in [Table 3](#TB1143-3){ref-type="table"} [@JR1143-33] . A random effects model was used for statistical heterogeneity across trials and a fixed effect model was used if no significant heterogeneity was present. Relative risks (RR) with corresponding 95 % CI were calculated. Heterogeneity was calculated using *I ^2^* test. Publication bias was assessed using a funnel plot. Statistical analyses were performed using RevMan software (Review Manager version 5.3; The Nordic Cochrane Centre, Copenhagen, Demark, The Cochrane Collaboration 2015).

###### PRISMA checklist.

  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  TITLE                                                                                                                                                                                                                                                                                                                                                   
  Title                                 1   Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           Mentioned as meta-analysis
  ABSTRACT                                                                                                                                                                                                                                                                                                                                                
  Structured summary                    2   Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number:   A detailed abstract with the necessary information has been provided
  INTRODUCTION                                                                                                                                                                                                                                                                                                                                            
  Rationale/                            3   Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                Provided
  Objectives                            4   Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    Provided
  METHODS                                                                                                                                                                                                                                                                                                                                                 
  Protocol and registration/            5   Indicate if a review protocol exists, if and where it can be accessed (e. g., Web address), and, if available, provide registration information including registration number.                                                                                                                                Not applicable with Meta-analysis
  Eligibility criteria                  6   Specify study characteristics (e. g., PICOS, length of follow-up) and report characteristics (e. g., years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                      Provided
  Information sources                   7   Describe all information sources (e. g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                   Provided
  Search                                8   Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 Provided
  Study selection                       9   State the process for selecting studies (i. e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                    Provided
  Data collection process              10   Describe method of data extraction from reports (e. g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                   Provided
  Data items                           11   List and define all variables for which data were sought (e. g., PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                        Provided
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        Provided
  Summary measures                     13   State the principal summary measures (e. g., risk ratio, difference in means).                                                                                                                                                                                                                                Provided
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e. g., I ^2^ ) for each meta-analysis.                                                                                                                                                    Provided
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (e. g., publication bias, selective reporting within studies).                                                                                                                                                                 Provided
  Additional analyses                  16   Describe methods of additional analyses (e. g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                             Provided
  RESULTS                                                                                                                                                                                                                                                                                                                                                 
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               Provided
  Study characteristics                18   For each study, present characteristics for which data were extracted (e. g., study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                 Provided
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome-level assessment (see Item 12).                                                                                                                                                                                                     Provided
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                  Provided
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       Provided
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see Item 15).                                                                                                                                                                                                                               Provided
  Additional analysis                  23   Give results of additional analyses, if done (e. g., sensitivity or subgroup analyses, meta-regression \[see Item 16\]).                                                                                                                                                                                      Provided
  DISCUSSION                                                                                                                                                                                                                                                                                                                                              
  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e. g., health care providers, users, and policy makers).                                                                                                                        Provided
  Limitations                          25   Discuss limitations at study and outcome level (e. g., risk of bias), and at review level (e. g., incomplete retrieval of identified research, reporting bias).                                                                                                                                               Provided
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                       Provided
  FUNDING                                                                                                                                                                                                                                                                                                                                                 
  Funding                              27   Describe sources of funding for the systematic review and other support (e. g., supply of data); role of funders for the systematic review                                                                                                                                                                    Provided
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------

Results
=======

Adenoma detection rate
----------------------

An initial pooled analysis of eight RCTs (5681 patients) was performed, which showed a numerically higher ADR in the CC group compared to the SC group, but results were not statistically significant (OR 1.08, 95 % CI 0.97 -- 1.21; I ^2^ 56 %) ( [Fig. 2a](#FI1143-2){ref-type="fig"} ). However, when only high-quality RCTs were included (Jadad score  ≥ 3) as per the primary aim of this study, there were seven RCTs with a total of 4,681 patients (2,344 patients in the CC group, 2,337 patients in the SC group). We were unbale to include some studies with a score of 3 or more, as they lacked information regarding ADR/APP [@JR1143-22] [@JR1143-24] [@JR1143-30] . ADR was significantly higher in the CC group (OR 1.18, 95 % CI 1.03 -- 1.33) ( [Fig. 2b](#FI1143-2){ref-type="fig"} ). There was no significant heterogeneity in the ADR analysis (I ^2^  = 0 %). Publication bias for studies included for ADR was assessed using a funnel plot ( [Fig. 3](#FI1143-3){ref-type="fig"} ).

![ Forest plot of pooled estimates of adenoma detection rate using cap-assisted colonoscopy compared to standard colonoscopy. **a** Results with all eligible studies. **b** Results with only high-quality studies (Jadad score ≥ 3). **c** Results with only high-quality studies using random effects.](10-1055-a-0650-4258-i1143ei2){#FI1143-2}

![ Funnel plot showing publication bias.](10-1055-a-0650-4258-i1143ei3){#FI1143-3}

Analysis was also performed using a random effects model. Analysis of the seven high-quality RCTs using the random effects model showed significantly higher ADR in the CC group (OR 1.104, 95 % CI 1.02 -- 1.18) ( [Fig. 2c](#FI1143-2){ref-type="fig"} ).

Sensitivity analysis was not performed based on our stringent criteria to include only high-quality studies with Jadad score ≥ 3 which carry a very low risk for bias [@JR1143-34] [@JR1143-35] [@JR1143-36] .

Mean adenomas detected per person
---------------------------------

Analysis for APP included six RCTs with 4,368 patients. There were 2184 patients in each group. Use of cap led to a mean difference of 0.16 (95 % CI 0.02 -- 0.30) additional APP ( [Fig. 4](#FI1143-4){ref-type="fig"} ). Significant heterogeneity was found in the studies reporting mean APP (I ^2^  = 68 %).

![ Forest plot of pooled estimate of adenoma per person (APP) showing higher detection of average adenoma per person using cap compared to standard colonoscopy.](10-1055-a-0650-4258-i1143ei4){#FI1143-4}

Large adenoma detection rate
----------------------------

Analysis for large adenomas ( ≥ 10 mm) included four RCTs with 2468 patients. There were 1247 patients in the CC group compared to 1221 patients in the SC group. Use of cap led to a statistically significantly higher rate of detection of large adenomas (OR 1.49, 95 % CI 1.03 -- 2.15, *P*  \< 0.005) with heterogeneity of (I ^2^  = 44 %) ( [Fig. 5](#FI1143-5){ref-type="fig"} ).

![ Figure plot of pooled estimate of adenomas \> 10 mm, showing significant improved detection with CAP assisted colonoscopy compared to standard colonoscopy](10-1055-a-0650-4258-i1143ei5){#FI1143-5}

Sessile serrated adenoma detection rate
---------------------------------------

Analysis for sessile serrated adenoma (SSA) included only three RCTs with 2872 patients. There were 1427 patients in the CC group compared to 1445 patients in the SC group. Use of cap did not lead to any significant difference in detection of SSA with (OR 1.12, 95 % CI 0.66 -- 1.88) and a significant heterogeneity of (I ^2^  = 76 %) ( [Fig. 6](#FI1143-6){ref-type="fig"} ).

![ Figure plot of pooled estimate of sessile serrated adenoma (SSA) showing no significant improvement in the detection of proximal adenomas.](10-1055-a-0650-4258-i1143ei6){#FI1143-6}

Cecal intubation rate and time
------------------------------

Pooled analysis of 17 studies that included 5416 patients in the CC and 5401 patients in the SC groups were utilized to evaluate the cecal intubation rate ( [Fig. 7a](#FI1143-7){ref-type="fig"} ). The cecal intubation rate in the CC group was 96.3 % compared to 94.5 % with SC. Use of cap improved cecal intubation (OR 1.61, 95 % CI 1.33 -- 1.95) when compared to SC ( *P*  \< 0.001). Low heterogeneity was identified among studies ( *I ^2^*  = 2 %).

![ Forest plot of pooled estimates of cecal intubation rate ( **a** ) and cecal intubation time ( **b** ) showing improved rates and lesser time with cap compared to standard colonoscopy](10-1055-a-0650-4258-i1143ei7){#FI1143-7}

Thirteen studies were used to analyze the impact of cap on cecal intubation time ( [Fig. 7b](#FI1143-7){ref-type="fig"} ). The CC group included 3014 patients and the SC group included 3037 patients. Use of cap decreased the cecal intubation time by an average of 0.88 minutes (95 % CI 0.37 -- 1.39) or 53 seconds. However, significant heterogeneity was detected among these studies ( *I ^2^*  = 87 %).

Discussion
==========

Results of our meta-analysis indicate that use of cap improves detection of adenomas. An improvement in ADR, mean number of adenomas detected per patient and large adenomas was seen with CC. For ADR we included only trials with a Jadad score ≥ 3 to ensure only high-quality trials. The Jadad score is the most widely used scale to measure the quality of RCTs. Overall, we found seven RCTs with a Jadad score ≥ 3. This study differs from a previous meta-analysis [@JR1143-13] in that we excluded the study by Lee [@JR1143-25] as it employed suboptimal techniques for randomization. Proper technique includes a statistician and computer-generated randomization, where as in the study by Lee et al, only sealed envelopes were used without mention of statistician or a computer-generated sequence [@JR1143-25] . Furthermore, in that study, the quality of bowel preparation was significantly less satisfactory. They classified the quality of their bowel preparation into three categories: "excellent," "fair," and "poor." In the results, they noted that a higher proportion of patients in the CC group had less satisfactory bowel preparation (excellent/fair/poor bowel preparation in CC group were 52.7:33.5:13.8 % vs. SC group\'s 62.3:28.1:9.6 %, respectively, *P*  = 0.006). They also reported an ADR that was lower with use of CAP. The inferior bowel preparation in the CC group could have negatively impacted the ADR. As a matter of fact, this is the only trial where use of CAP has been associated with lower ADR compared to standard colonoscopy. All other trials have shown either no difference or higher ADR with CAP.

ADR is a quality indicator for colonoscopy and has been shown to be associated with improved outcomes related to interval cancer and colorectal cancer-related mortality. While this meta-analysis shows an overall improvement in ADR with CC, individual studies have shown variable results. The study by Pohl et al *.* [@JR1143-18] which was the largest study evaluating CC in the United States showed that the impact on the individual endoscopist ADR is variable. The range of impact was from 20 % improvement to 15 % decrease in the individual ADR with CC. They also showed that those who preferred

CAP showed an improvement in ADR. We have also shown an improvement in the average number of adenomas detected per patient.

CC also improved detection of large adenomas, however, a statistically significant improvement in mean number of diminutive adenomas was not found. We suspect this may be due, in part, to the differing sizes of small adenomas reported (5 mm vs. 6 mm). There was no significant improvement in detection of proximal adenomas or SSAs as the RCTs that were performed were not adequately powered to detect any difference in the above outcomes.

Our meta-analysis has some limitations. The study populations in the studies were very diverse with studies being performed in Asia, North America, and Europe. That, however, improves generalizability of the results. Given the obvious lack of blinding of the endoscopists and the nature of such studies evaluating devices to improve ADR, investigator bias is unavoidable. Endoscopist experience in the different studies also varies widely and could not be accounted for with respect to the impact of CC on ADR. Use of a cap with colonoscopy requires some training, adjustment, and experience. This factor was not adjusted for or studied in the trials, making it difficult to gauge the impact of that on the results.

A cap is a simple, inexpensive and easy-to-use tool to improve the quality of colonoscopy. The cost of the cap, albeit low, appears to be the only negative factor weighing against its use in daily clinical practice. To derive maximum benefit from cap, endoscopists need to gain experience with the device. As the cap projects outside the tip of the colonoscope, it may appear to limit the angle of view. This must be compensated for withi adequate deflection of the tip and use of the edge of the cap to flatten the haustral folds to expose their proximal aspects and derive the maximum benefit. Furthermore, the benefit of CC has been shown to significantly extend visualization of the right colon in a colonoscopic training model [@JR1143-37] . Use of cap offers other secondary benefits such as improved cecal intubation rates and stabilization of the tip of the scope during polypectomy.

Conclusion
==========

In conclusion, this meta-analysis showed that there is a marginal and statistically significant benefit to use of a cap during colonoscopy to improve ADR and cecal intubation rate and reduce cecal intubation time. Further research needs to be conducted to determine if there are specific patient subgroups that may benefit more from use of a cap, whether to train endoscopists in use of the device, and identify appropriate training methods.
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